Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (53 quarters reported)
$2.12B in Q2 2013 → $9.59B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Nuvalent Inc | 22.2% | Unchanged | 17,248,450 | $2.13B |
| BS Brookdale Sr Living Inc | 6.1% | Unchanged | 306,885,000 | $586M |
| Revolution Medicines Inc | 4.7% | Added 4.1% | 2,392,000 | $448M |
| PP Praxis Precision Medicines I | 3.4% | Unchanged | 963,351 | $323M |
| Viatris Inc | 3.3% | Unchanged | 20,206,170 | $321M |
| CD Centene Corp Del | 3.3% | Trimmed 17% | 4,901,000 | $315M |
| Revolution Medicines Inc | 2.6% | New | 200,000,000 | $252M |
| UT United Therapeutics Corp Del | 2.6% | Unchanged | 457,000 | $248M |
| AP Arrowhead Pharmaceuticals In | 2.5% | Unchanged | 200,000,000 | $241M |
| Legend Biotech Corp | 2.5% | Added 5.9% | 8,137,638 | $235M |
| Cogent Biosciences Inc | 2.0% | Trimmed 45% | 5,006,104 | $194M |
| Genmab A/s | 2.0% | Added 179% | 6,865,000 | $189M |
| BS Brookdale Sr Living Inc | 2.0% | Unchanged | 11,637,032 | $187M |
| Vera Therapeutics Inc | 1.8% | Added 5.2% | 3,916,400 | $168M |
| Ionis Pharmaceuticals Inc | 1.6% | Unchanged | 1,979,669 | $157M |
| Celcuity Inc | 1.6% | Trimmed 15% | 1,451,014 | $152M |
| Biocryst Pharmaceuticals Inc | 1.6% | Added 0.4% | 15,096,403 | $151M |
| NP Newamsterdam Pharma Company | 1.5% | Unchanged | 4,264,789 | $145M |
| AH Acadia Healthcare Company In | 1.4% | Unchanged | 4,520,000 | $133M |
| Tango Therapeutics Inc | 1.4% | Added 1.1% | 4,190,611 | $131M |
| Adapthealth Corp | 1.2% | Unchanged | 11,477,730 | $120M |
| Pharvaris N V | 1.2% | Added 8.0% | 3,376,042 | $117M |
| Celcuity Inc | 1.2% | New | 100,000,000 | $114M |
| AP Arrowhead Pharmaceuticals In | 1.2% | Trimmed 12% | 1,389,055 | $113M |
| DT Dianthus Therapeutics Inc | 1.1% | Added 10% | 1,125,313 | $110M |
| Larimar Therapeutics Inc | 1.1% | Unchanged | 35,606,974 | $109M |
| Mineralys Therapeutics Inc | 1.1% | New | 3,958,000 | $107M |
| Alignment Healthcare Inc | 1.1% | Unchanged | 61,000,000 | $104M |
| Ideaya Biosciences Inc | 1.1% | Added 77% | 2,714,503 | $101M |
| Xenon Pharmaceuticals Inc | 1.0% | Unchanged | 1,615,696 | $97.5M |
| Ionis Pharmaceuticals Inc | 1.0% | Unchanged | 60,000,000 | $93.1M |
| Savara Inc | 0.9% | Unchanged | 13,569,000 | $83.6M |
| LH Lantheus Hldgs Inc | 0.9% | Trimmed 9.1% | 752,999 | $83.5M |
| Syndax Pharmaceuticals Inc | 0.9% | Unchanged | 3,779,900 | $82.6M |
| Zenas Biopharma Inc | 0.8% | Added 3.4% | 67,200,000 | $80.3M |
| Biomarin Pharmaceutical Inc | 0.8% | Added 57% | 1,332,836 | $76.3M |
| Pfizer Inc | 0.8% | Unchanged | 3,040,000 | $73.2M |
| Indivior Pharmaceuticals Inc | 0.7% | Trimmed 47% | 1,648,895 | $67.7M |
| BR Bio Rad Labs Inc | 0.7% | Unchanged | 226,070 | $66.4M |
| Ars Pharmaceuticals Inc | 0.6% | Unchanged | 7,503,812 | $60.1M |
| Stoke Therapeutics Inc | 0.6% | Unchanged | 1,823,500 | $59.7M |
| Structure Therapeutics Inc | 0.6% | Added 41% | 1,086,000 | $58.3M |
| Envista Holdings Corporation | 0.6% | Unchanged | 2,210,100 | $58.2M |
| IM Inspire Med Sys Inc | 0.6% | Trimmed 52% | 1,296,862 | $57.9M |
| Caredx Inc | 0.6% | Trimmed 8.8% | 1,997,618 | $56.9M |
| Boston Scientific Corp | 0.6% | New | 1,315,000 | $56.1M |
| Belite Bio Inc | 0.6% | Added 17% | 357,199 | $55M |
| PM Parabilis Medicines Inc | 0.5% | New | 1,880,704 | $51.5M |
| Certara Inc | 0.5% | Trimmed 3.8% | 7,512,928 | $49.2M |
| Disc Medicine Inc | 0.5% | Unchanged | 657,000 | $48.1M |
| Livanova PLC | 0.5% | Unchanged | 34,280,000 | $46.5M |
| BO Bridgebio Oncology Therapeut | 0.4% | Unchanged | 4,885,446 | $37.2M |
| Tyra Biosciences Inc | 0.3% | Added 85% | 1,017,000 | $32.5M |
| Monopar Therapeutics Inc | 0.3% | Unchanged | 323,745 | $30M |
| Sionna Therapeutics Inc | 0.3% | Trimmed 30% | 680,916 | $30M |
| IH Immunocore Hldgs PLC | 0.3% | Unchanged | 30,000,000 | $27.1M |
| AP Avalyn Pharmaceuticals Inc | 0.3% | New | 731,000 | $24.1M |
| Foghorn Therapeutics Inc | 0.2% | Unchanged | 4,394,367 | $21.4M |
| Beta Bionics Inc | 0.2% | Unchanged | 1,324,000 | $20.7M |
| Alnylam Pharmaceuticals Inc | 0.2% | Unchanged | 67,935 | $20.5M |
Showing top 60 of 82 positions.
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | New | +200,000,000 | +$252M | 2.6% |
| Mirum Pharmaceuticals Inc | Exited | −70,000,000 | −$209M | — |
| Cogent Biosciences Inc | Trimmed | −4,037,799 | −$156M | 2.0% |
| Genmab A/s | Added | +4,403,000 | +$121M | 2.0% |
| Celcuity Inc | New | +100,000,000 | +$114M | 1.2% |
| Mineralys Therapeutics Inc | New | +3,958,000 | +$107M | 1.1% |
| Catalyst Pharmaceuticals Inc | Exited | −3,943,600 | −$97.6M | — |
| Neurocrine Biosciences Inc | Exited | −610,000 | −$80.4M | — |
| DO Day One Biopharmaceuticals I | Exited | −3,723,131 | −$79.8M | — |
| Enhabit Inc | Exited | −4,747,746 | −$66.9M | — |
Showing the 10 largest of 52 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Arrowhead Pharmaceuticals In | New | +200,000,000 | +$207M | 2.4% |
| IP Indivior PLC | Exited | −3,393,063 | −$122M | — |
| Indivior Pharmaceuticals Inc | New | +3,097,790 | +$94.4M | 1.1% |
| Syndax Pharmaceuticals Inc | New | +3,779,900 | +$88.3M | 1.0% |
| DT Dianthus Therapeutics Inc | New | +1,019,813 | +$85.6M | 1.0% |
| Pfizer Inc | New | +3,040,000 | +$85.4M | 1.0% |
| Neurocrine Biosciences Inc | Trimmed | −574,345 | −$75.7M | 0.9% |
| Zenas Biopharma Inc | New | +65,000,000 | +$67.3M | 0.8% |
| Genmab A/s | New | +2,462,000 | +$66.1M | 0.8% |
| Xenon Pharmaceuticals Inc | Added | +1,073,676 | +$62.4M | 1.1% |
Showing the 10 largest of 116 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| BS Brookdale Sr Living Inc | New | +306,885,000 | +$427M | 5.5% |
| Merus N V | Exited | −3,046,916 | −$287M | — |
| IP Indivior PLC | Trimmed | −3,593,748 | −$129M | 1.6% |
| CD Centene Corp Del | Trimmed | −2,598,002 | −$107M | 3.4% |
| Bristol-myers Squibb Co | Exited | −2,337,771 | −$105M | — |
| Celcuity Inc | Added | +980,470 | +$97.8M | 2.2% |
| Alignment Healthcare Inc | New | +61,000,000 | +$92.6M | 1.2% |
| Tandem Diabetes Care Inc | Exited | −100,000,000 | −$87.1M | — |
| Merck & Co Inc | Exited | −1,030,000 | −$86.4M | — |
| Pfizer Inc | Exited | −3,303,790 | −$84.2M | — |
Showing the 10 largest of 147 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oscar Health Inc | Exited | −11,649,591 | −$250M | — |
| CD Centene Corp Del | Added | +5,860,630 | +$209M | 4.9% |
| IL Integra Lifesciences Hldgs C | Exited | −174,364,000 | −$173M | — |
| Alnylam Pharmaceuticals Inc | Exited | −110,000,000 | −$143M | — |
| Ionis Pharmaceuticals Inc | New | +1,979,669 | +$130M | 2.0% |
| Bristol-myers Squibb Co | New | +2,337,771 | +$105M | 1.6% |
| Cogent Biosciences Inc | Added | +6,412,903 | +$92.1M | 2.0% |
| IP Indivior PLC | Trimmed | −3,580,349 | −$86.3M | 2.6% |
| Ionis Pharmaceuticals Inc | New | +60,000,000 | +$82.7M | 1.3% |
| IM Inspire Med Sys Inc | Added | +907,694 | +$67.4M | 1.2% |
Showing the 10 largest of 137 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Accolade Inc | Exited | −132,598,000 | −$131M | — |
| UT United Therapeutics Corp Del | Added | +265,400 | +$76.3M | 2.8% |
| Merck & Co Inc | New | +857,724 | +$67.9M | 1.2% |
| Dynavax Technologies Corp | Exited | −5,191,493 | −$67.3M | — |
| Alignment Healthcare Inc | Trimmed | −4,224,915 | −$59.1M | 0.1% |
| Vera Therapeutics Inc | Added | +2,298,117 | +$54.1M | 1.4% |
| Legend Biotech Corp | Added | +1,218,783 | +$43.3M | 1.9% |
| Neurocrine Biosciences Inc | Trimmed | −321,198 | −$40.4M | 2.7% |
| Tandem Diabetes Care Inc | New | +40,000,000 | +$38.5M | 0.7% |
| Chimerix Inc | Exited | −3,771,342 | −$32.1M | — |
Showing the 10 largest of 130 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| WH Waystar Hldg Corp | Exited | −3,295,260 | −$121M | — |
| UT United Therapeutics Corp Del | New | +275,226 | +$84.8M | 1.7% |
| Pfizer Inc | New | +3,347,296 | +$84.8M | 1.7% |
| Neurocrine Biosciences Inc | Added | +627,000 | +$69.3M | 3.3% |
| O& Owens & Minor Inc New | Exited | −4,911,979 | −$64.2M | — |
| Alignment Healthcare Inc | Trimmed | −2,736,829 | −$51M | 1.7% |
| AH Alphatec Hldgs Inc | Exited | −49,500,000 | −$46.7M | — |
| GN Galapagos Nv | Exited | −1,411,000 | −$38.8M | — |
| Insmed Inc | New | +458,000 | +$34.9M | 0.7% |
| Bicara Therapeutics Inc | Exited | −1,795,174 | −$31.3M | — |
Showing the 10 largest of 114 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Nuvalent Inc | Trimmed | −2,000,000 | −$157M | 26.7% |
| Kura Oncology Inc | Exited | −5,411,571 | −$106M | — |
| NP Newamsterdam Pharma Company | Added | +3,412,590 | +$87.7M | 2.1% |
| Dynavax Technologies Corp | Added | +5,172,263 | +$66M | 1.3% |
| Catalyst Pharmaceuticals Inc | Trimmed | −3,096,623 | −$64.6M | 1.2% |
| AH Alphatec Hldgs Inc | Trimmed | −68,000,000 | −$64.2M | 0.9% |
| Neurocrine Biosciences Inc | Trimmed | −454,590 | −$62.1M | 2.2% |
| WH Waystar Hldg Corp | Trimmed | −1,656,744 | −$60.8M | 2.3% |
| Surgery Partners Inc | Exited | −1,780,287 | −$57.4M | — |
| Cvs Health Corp | Exited | −874,800 | −$55M | — |
Showing the 10 largest of 433 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Insmed Inc | Exited | −151,408,000 | −$259M | — |
| BS Brookdale Sr Living Inc | Exited | −161,905,000 | −$163M | — |
| Alnylam Pharmaceuticals Inc | New | +100,000,000 | +$117M | 1.7% |
| AH Alphatec Hldgs Inc | New | +117,500,000 | +$106M | 1.6% |
| Gilead Sciences Inc | Exited | −1,491,000 | −$102M | — |
| Surgery Partners Inc | Trimmed | −2,927,000 | −$94.4M | 0.9% |
| Neurocrine Biosciences Inc | Added | +625,586 | +$72.1M | 2.3% |
| Catalyst Pharmaceuticals Inc | Trimmed | −2,897,671 | −$57.6M | 1.9% |
| Biontech Se | Trimmed | −419,500 | −$49.8M | 0.3% |
| IP Indivior PLC | New | +5,092,642 | +$49.7M | 0.7% |
Showing the 10 largest of 644 changes.
Loading...
